# OnCo record nct05086692 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05086692/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05086692", "NCT05086692" ;
  schema:name "A Beta-only IL-2 ImmunoTherapY Study"@en ;
  schema:alternateName "ABILITY-1"@en ;
  schema:description "A phase 1/2 trial of Pembrolizumab in renal cell carcinoma and non-small-cell lung cancer, run by Medicenna Therapeutics, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05086692/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05086692> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2021-08-27" ;
  onco:cancers <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/cervical/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> .